Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)

Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)

BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for locally advanced non-small-cell lung cancer (LA-NSCLC), whereas responses to anti-programmed cell death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) are heterogeneous. Though consolidation ICI followi...

Full description

Bibliographic Details
Main Authors: Yu Wang, Lei Deng, Jianyang Wang, Tao Zhang, Wenqing Wang, Xin Wang, Wenyang Liu, Yuqi Wu, Jima Lv, Qinfu Feng, Zongmei Zhou, Jie Wang, Luhua Wang, Zhijie Wang, Nan Bi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
immune checkpoint inhibitor
chemoradiotherapy
induction therapy
programmed cell death-1
non-small-cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1341584/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1341584/full

Similar Items